Microcap Ledger Immuneering Corp $IMRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
What the company doesAI summary of filing
Immuneering Corp is a late-stage clinical oncology company developing Deep Cyclic Inhibitors, a category of oral small-molecule cancer medicines designed to cyclically disrupt MAPK signaling pathways. The company's lead product candidate, atebimetinib (IMM-1-104), is in Phase 1/2a trials for advanced solid tumors and is expected to enter a Phase 3 registrational trial (MAPKeeper 301) for first-line pancreatic cancer in mid-2026; the company is pre-revenue and funds development through capital raises. Immuneering also has a second clinical-stage program, envometinib (IMM-6-415), and earlier-stage discovery programs targeting validated cancer signaling pathways; the company makes money by licensing its translational bioinformatics platform and insights to pharmaceutical partners for analyses of their compounds. [10-K 2026-03-06]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$30.73M | −$34.93M | $41.32M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | — | −$56.02M | −$45.34M | $128.65M | [10-K 2026-03-06] |
| FY ended Dec 2024 | — | −$61.04M | −$55.00M | $36.14M | [10-K 2026-03-06] |
- Quarterly cash burn
- −$17.47M
- Cash runway Estimate
- ~7.1 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2025-09-03; declared effective 2025-09-08 [S-3 2025-09-03]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-23 | Zeskind Benjamin J. | buy | 2,400 | $4.56 | [4 2026-06-24] |
| 2026-06-15 | Hall Brett Matthew | buy | 6,035 | $4.15 | [4 2026-06-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-07-28 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-15 | 8-K | Director or officer change |
| 2026-06-11 | 8-K | Shareholder vote results |
| 2026-06-01 | 8-K | Other events |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-15 | 8-K | Results of operations |
| 2026-04-20 | DEF 14A | Proxy statement |
| 2026-03-06 | 10-K | Annual report |
| 2026-03-06 | 8-K | Results of operations |
| 2026-01-22 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $IMRX
Email me when Immuneering Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.